Sana Biotechnology (NASDAQ:SANA) Stock Rating Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Sana Biotechnology from “sell” to “hold.” Across analysts, the stock has a “Moderate Buy” consensus rating and an average price target of $9.60.
• Sana reported quarterly EPS of -$0.14, beating analysts’ consensus estimate of -$0.15; analysts forecast full-year EPS of -$0.72.
• Institutional investors own 88.23% of Sana shares, with BlackRock, Canada Pension Plan Investment Board, and Bank of America among those that recently established positions.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other equities analysts have also commented on SANA. Bank of America lowered their price objective on Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. TD Cowen upgraded Sana Biotechnology to a "strong-buy" rating in a research report on Monday, August 24th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Sana Biotechnology in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Sana Biotechnology currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.60.

Sana Biotechnology Trading Up 1.3%

Shares of NASDAQ SANA opened at $2.37 on Friday. The stock has a market cap of $709.48 million, a price-to-earnings ratio of -4.47 and a beta of 2.30. The company has a 50 day simple moving average of $2.88 and a two-hundred day simple moving average of $3.35. Sana Biotechnology has a 12 month low of $2.22 and a 12 month high of $5.49.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. Analysts forecast that Sana Biotechnology will post -0.72 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors have recently modified their holdings of SANA. BlackRock Inc. purchased a new position in shares of Sana Biotechnology during the 2nd quarter worth $58,196,000. Canada Pension Plan Investment Board bought a new stake in Sana Biotechnology in the second quarter worth about $35,662,000. Bank of America Corp DE bought a new stake in Sana Biotechnology in the second quarter worth $20,062,000. Alphabet Inc. acquired a new position in shares of Sana Biotechnology in the 2nd quarter worth approximately $9,816,000. Finally, Deutsche Bank AG bought a new position in shares of Sana Biotechnology in the 2nd quarter worth $2,251,000. 88.23% of the stock is owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company's approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.